These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32965687)

  • 1. Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in Patients With CHB.
    Zhang BH; Cai YS; Song JL; Lyu T; Yang J; Jiang L; Yang JY
    Hepatology; 2021 Apr; 73(4):1621-1622. PubMed ID: 32965687
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Huang R; Wang J; Wu W; Yan X; Wu C
    Hepatology; 2020 Jun; 71(6):2173-2174. PubMed ID: 31858599
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins and risk reduction in hepatocellular carcinoma: fact or fiction?
    Singh PP; Singh S
    J Clin Oncol; 2012 Jul; 30(20):2569-70; author reply 2570-2571. PubMed ID: 22689810
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence.
    Siegel AB; El-Serag HB
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):493-5. PubMed ID: 23984995
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Muñoz AE; Rodger EG
    Hepatology; 2024 Jul; 80(1):E8. PubMed ID: 38466821
    [No Abstract]   [Full Text] [Related]  

  • 6. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.
    Cho Y; Kim MS; Nam CM; Kang ES
    Sci Rep; 2019 Feb; 9(1):1467. PubMed ID: 30728421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis.
    Chang Y; Liu Q; Zhou Z; Ding Y; Yang M; Xu W; Chen K; Zhang Q; Wang Z; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820934881. PubMed ID: 32552476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
    Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
    J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Tsan YT; Lee CH; Wang JD; Chen PC
    J Clin Oncol; 2012 Feb; 30(6):623-30. PubMed ID: 22271485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden.
    Björkhem-Bergman L; Backheden M; Söderberg Löfdal K
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1101-6. PubMed ID: 25074765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence?
    Carrat F
    Clin Res Hepatol Gastroenterol; 2014 Feb; 38(1):9-11. PubMed ID: 24183917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
    Li Z; Zhang Y; Li Y; Lan J; Hu Y; Yu J; Meng Q; Zou B
    Hepatology; 2024 Jun; 79(6):E169-E170. PubMed ID: 38441957
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Sharpton S; Loomba R
    Hepatology; 2024 Jul; 80(1):E9-E10. PubMed ID: 38466795
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter to the editor: Aspirin use and the risk of hepatocellular carcinoma.
    Lai SW
    Hepatology; 2022 Dec; 76(6):E138-E139. PubMed ID: 35844049
    [No Abstract]   [Full Text] [Related]  

  • 15. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
    Tseng CH
    Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
    Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
    Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin use and risk of hepatocellular carcinoma in a U.S. population.
    McGlynn KA; Divine GW; Sahasrabuddhe VV; Engel LS; VanSlooten A; Wells K; Yood MU; Alford SH
    Cancer Epidemiol; 2014 Oct; 38(5):523-7. PubMed ID: 25113938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.
    Wang J; Li X
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1603-1609. PubMed ID: 33405428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.
    Li X; Sheng L; Liu L; Hu Y; Chen Y; Lou L
    BMC Gastroenterol; 2020 Apr; 20(1):98. PubMed ID: 32272891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study.
    German MN; Lutz MK; Pickhardt PJ; Bruce RJ; Said A
    J Clin Gastroenterol; 2020 Sep; 54(8):733-740. PubMed ID: 31567625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.